Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwMyeloma 2017 | Liquid biopsies for multiple myeloma: the attractions and limits

Jens Lohr • 18 Oct 2017
iwMyeloma 2017
Multiple Myeloma

Technological advances have allowed for whole genome, exome and transcriptome sequencing of circulating multiple myeloma (MM) cells and cell-free tumor DNA. In this video, Jens Lohr, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA, highlights the advantages of this. Dr Lohr also addresses the limitation of liquid biopsies, including patient selection and standardization. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.

More from Jens Lohr

MRD detection in myeloma: single cell RNAseq, protein-based & VDJ sequencing 6:28
MRD detection in myeloma: single cell RNAseq, protein-based & VDJ sequencing
Angela Dispenzieri et al. • 10 Sep 2018
Is MRD testing ready for prime time in myeloma? 10:35
Is MRD testing ready for prime time in myeloma?
Angela Dispenzieri et al. • 10 Sep 2018
The biases of using bone marrow biopsies for multiple myeloma 0:49
The biases of using bone marrow biopsies for multiple myeloma
Jens Lohr • 18 Oct 2017

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals